Bioteque
Bioteque Corporation manufactures and sells medical device in Asia, South America, North America, and internationally. The company provides medical disposables for use in hemodialysis access, endovascular treatment, and other fields. It offers dialysis products, including hemodialysis bloodlines, A.V.F. needles, and hemodialysis cathers; interventional radiology products, such as pigtail drainage… Read more
Bioteque (4107) - Net Assets
Latest net assets as of September 2025: NT$3.44 Billion TWD
Based on the latest financial reports, Bioteque (4107) has net assets worth NT$3.44 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.49 Billion) and total liabilities (NT$1.06 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.44 Billion |
| % of Total Assets | 76.48% |
| Annual Growth Rate | 8.61% |
| 5-Year Change | 29.16% |
| 10-Year Change | 81.33% |
| Growth Volatility | 11.78 |
Bioteque - Net Assets Trend (2006–2024)
This chart illustrates how Bioteque's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bioteque (2006–2024)
The table below shows the annual net assets of Bioteque from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.44 Billion | +7.86% |
| 2023-12-31 | NT$3.19 Billion | +5.22% |
| 2022-12-31 | NT$3.03 Billion | +8.16% |
| 2021-12-31 | NT$2.80 Billion | +5.22% |
| 2020-12-31 | NT$2.66 Billion | +7.08% |
| 2019-12-31 | NT$2.49 Billion | +7.52% |
| 2018-12-31 | NT$2.31 Billion | +8.30% |
| 2017-12-31 | NT$2.14 Billion | +2.86% |
| 2016-12-31 | NT$2.08 Billion | +9.47% |
| 2015-12-31 | NT$1.90 Billion | +0.85% |
| 2014-12-31 | NT$1.88 Billion | +16.45% |
| 2013-12-31 | NT$1.62 Billion | +25.89% |
| 2012-12-31 | NT$1.28 Billion | +3.44% |
| 2011-12-31 | NT$1.24 Billion | -0.18% |
| 2010-12-31 | NT$1.24 Billion | -0.77% |
| 2009-12-31 | NT$1.25 Billion | +5.62% |
| 2008-12-31 | NT$1.19 Billion | +1.15% |
| 2007-12-31 | NT$1.17 Billion | +50.63% |
| 2006-12-31 | NT$778.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bioteque's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1910.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$1.83 Billion | 53.16% |
| Other Components | NT$1.61 Billion | 46.84% |
| Total Equity | NT$3.44 Billion | 100.00% |
Bioteque Competitors by Market Cap
The table below lists competitors of Bioteque ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dagi Yatirim Holding AS
IS:DAGHL
|
$198.92 Million |
|
Fraser and Neave Limited
PINK:FNEVF
|
$198.99 Million |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
$199.04 Million |
|
Incar Financial Service Co. Ltd.
KQ:211050
|
$199.04 Million |
|
Ningbo Fubang
SHG:600768
|
$198.92 Million |
|
Styrenix Performance Materials Limited
NSE:STYRENIX
|
$198.92 Million |
|
Taiwan FamilyMart Co Ltd
TWO:5903
|
$198.91 Million |
|
Dongwoon Anatech Co Ltd
KQ:094170
|
$198.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioteque's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,190,127,000 to 3,440,970,000, a change of 250,843,000 (7.9%).
- Net income of 528,260,000 contributed positively to equity growth.
- Dividend payments of 311,843,000 reduced retained earnings.
- Other comprehensive income decreased equity by 524,835,000.
- Other factors increased equity by 559,261,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$528.26 Million | +15.35% |
| Dividends Paid | NT$311.84 Million | -9.06% |
| Other Comprehensive Income | NT$-524.84 Million | -15.25% |
| Other Changes | NT$559.26 Million | +16.25% |
| Total Change | NT$- | 7.86% |
Book Value vs Market Value Analysis
This analysis compares Bioteque's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.71x to 2.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | NT$10.16 | NT$119.00 | x |
| 2007-12-31 | NT$14.87 | NT$119.00 | x |
| 2008-12-31 | NT$14.85 | NT$119.00 | x |
| 2009-12-31 | NT$15.69 | NT$119.00 | x |
| 2010-12-31 | NT$15.58 | NT$119.00 | x |
| 2011-12-31 | NT$15.48 | NT$119.00 | x |
| 2012-12-31 | NT$16.27 | NT$119.00 | x |
| 2013-12-31 | NT$20.04 | NT$119.00 | x |
| 2014-12-31 | NT$21.52 | NT$119.00 | x |
| 2015-12-31 | NT$24.18 | NT$119.00 | x |
| 2016-12-31 | NT$29.82 | NT$119.00 | x |
| 2017-12-31 | NT$30.71 | NT$119.00 | x |
| 2018-12-31 | NT$33.22 | NT$119.00 | x |
| 2019-12-31 | NT$35.75 | NT$119.00 | x |
| 2020-12-31 | NT$38.28 | NT$119.00 | x |
| 2021-12-31 | NT$40.28 | NT$119.00 | x |
| 2022-12-31 | NT$43.53 | NT$119.00 | x |
| 2023-12-31 | NT$45.82 | NT$119.00 | x |
| 2024-12-31 | NT$49.65 | NT$119.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioteque utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.35%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.49%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.35x
- Recent ROE (15.35%) is above the historical average (15.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 7.36% | 11.64% | 0.38x | 1.68x | NT$-20.59 Million |
| 2007 | 26.36% | 55.20% | 0.34x | 1.41x | NT$191.87 Million |
| 2008 | 14.45% | 26.18% | 0.38x | 1.45x | NT$52.83 Million |
| 2009 | 12.65% | 20.32% | 0.45x | 1.38x | NT$33.23 Million |
| 2010 | 13.88% | 21.01% | 0.49x | 1.36x | NT$48.26 Million |
| 2011 | 10.36% | 16.91% | 0.47x | 1.31x | NT$4.50 Million |
| 2012 | 12.96% | 19.74% | 0.52x | 1.27x | NT$37.95 Million |
| 2013 | 13.32% | 22.47% | 0.48x | 1.24x | NT$53.63 Million |
| 2014 | 15.46% | 25.89% | 0.48x | 1.25x | NT$102.73 Million |
| 2015 | 16.64% | 25.07% | 0.50x | 1.32x | NT$126.00 Million |
| 2016 | 17.24% | 25.46% | 0.55x | 1.23x | NT$150.50 Million |
| 2017 | 14.22% | 21.40% | 0.54x | 1.23x | NT$90.26 Million |
| 2018 | 17.50% | 25.11% | 0.58x | 1.20x | NT$173.59 Million |
| 2019 | 18.66% | 24.97% | 0.63x | 1.18x | NT$215.36 Million |
| 2020 | 18.34% | 25.09% | 0.55x | 1.34x | NT$222.24 Million |
| 2021 | 15.38% | 23.62% | 0.47x | 1.38x | NT$150.94 Million |
| 2022 | 16.28% | 24.55% | 0.45x | 1.48x | NT$190.34 Million |
| 2023 | 14.19% | 23.27% | 0.42x | 1.45x | NT$133.54 Million |
| 2024 | 15.35% | 25.49% | 0.45x | 1.35x | NT$184.16 Million |
Industry Comparison
This section compares Bioteque's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,786,643,778
- Average return on equity (ROE) among peers: 10.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioteque (4107) | NT$3.44 Billion | 7.36% | 0.31x | $198.92 Million |
| St.Shine Optical Co Ltd (1565) | $5.39 Billion | 29.48% | 0.60x | $147.19 Million |
| Nang Kuang Pharmaceutical Co Ltd (1752) | $2.19 Billion | 9.94% | 0.50x | $46.91 Million |
| Maxigen Biotech Inc (1783) | $1.14 Billion | 7.68% | 0.11x | $53.63 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $107.95 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 12.60% | 0.47x | $41.85 Million |
| Sunder Biomedical Tech. Co., Ltd. (4115) | $790.45 Million | 1.68% | 0.80x | $2.11K |
| BenQ Medical Technology (4116) | $1.10 Billion | 2.62% | 0.78x | $25.45 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.26 Billion | 10.49% | 0.61x | $128.74 Million |
| Unicon Optical Co., Ltd. (4150) | $963.23 Million | 21.57% | 0.59x | $22.68 Million |